Format

Send to

Choose Destination
Urol Clin North Am. 2014 May;41(2):315-26. doi: 10.1016/j.ucl.2014.01.007.

Screening and detection advances in magnetic resonance image-guided prostate biopsy.

Author information

1
Department of Urology, David Geffen School of Medicine at UCLA, 10945 LeConte Avenue, PVUB Suite 3361, Los Angeles, CA 90095, USA.
2
Department of Urology, David Geffen School of Medicine at UCLA, 10945 LeConte Avenue, PVUB Suite 3361, Los Angeles, CA 90095, USA. Electronic address: lmarks@mednet.ucla.edu.

Abstract

Multiparametric magnetic resonance imaging (MRI) has provided a method for visualizing prostate cancer. MRI-ultrasonography fusion allows prostate biopsy to be performed quickly, on an outpatient basis, using the transrectal technique. Targeted biopsies are more sensitive for detection of prostate cancer than nontargeted, systematic biopsies and detect more significant prostate cancers and fewer insignificant cancers than conventional biopsies. A negative MRI scan should not defer biopsy. Two groups who will especially benefit from targeted prostate biopsy are men with low-risk lesions in active surveillance and men with increased prostate-specific antigen levels and previous negative conventional biopsies.

KEYWORDS:

Fusion biopsy; Magnetic resonance imaging; Prostate cancer; Prostate-specific antigen; Targeted prostate biopsy; Transrectal ultrasonography; Ultrasonography

PMID:
24725492
PMCID:
PMC3986723
DOI:
10.1016/j.ucl.2014.01.007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center